Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant

Pegvisomant monotherapy is effective and safe in treatment of acromegaly. However, some clinicians combine pegvisomant with somatostatin analogues (SSA) or dopamine agonist (DA). In this analysis of ACROSTUDY, a long-term non-interventional study, the use of combination regimens was evaluated. Based...

Descripción completa

Detalles Bibliográficos
Autores principales: Strasburger, Christian J, Mattsson, Anders, Wilton, Patrick, Aydin, Ferah, Hey-Hadavi, Judith, Biller, Beverly M K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863474/
https://www.ncbi.nlm.nih.gov/pubmed/29371335
http://dx.doi.org/10.1530/EJE-17-0996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863474/
https://www.ncbi.nlm.nih.gov/pubmed/29371335
http://dx.doi.org/10.1530/EJE-17-0996

Ejemplares similares